Skip to main content

Nonalcoholic Fatty Liver Disease News (Page 2)

Related terms: Nonalcoholic Steatohepatitis, Idiopathic Fatty Liver, Steatosis, Steatohepatitis, Fatty Liver, NASH, NAFLD, MASLD, Metabolic Dysfunction-Associated Steatotic Liver Disease

Fatty Liver Disease Now Affects 4 in 10 U.S. Adults

WEDNESDAY, Nov. 13, 2024 – Obesity, alcohol use and other factors are driving up rates of fatty liver disease among American adults, new research warns. By 2018, federal data showed that 42% of...

GLP-1 RA Use Linked to Reduced Cirrhosis Risk in MASLD, Diabetes

TUESDAY, Sept. 17, 2024 – For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with...

FDA Grants Accelerated Approval for Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

CONSHOHOCKEN, Pa., March 14, 2024 (GLOBE NEWSWIRE) – Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

Wegovy, semaglutide, orlistat